Please login to the form below
Singulair
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Singulair was produced by Merck & Co..
India denies patent on Pfizer's Xeljanz
Earlier cases have involved Novartis' cancer drug Glivec (imatinib), Roche 's Pegasys (peginterferon alfa-2a) for hepatitis, Merck &Co's asthma treatment Singulair (montelukast), Gilead's HIV drug Viread (tenofovir) and
Merck & Co's cancer drug Keytruda gaining traction in US
Merck's third-quarter results were hit as expected by the lingering effect of patent expiries on key products such as cancer drug Temodar (temozolomide) and Singulair (montelukast) for asthma, as
Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte
sales of asthma drug Singulair (montelukast) on generic competition, as well as a 14 per cent drop in net income to $781m.
Who tops the pharma list?
By the end of 2012, Advair (GSK - $8.2bn), Singulair (Merck - $5.5bn) and Diovan (Novartis - $5.7bn) would be among many billion-dollar brands to lose exclusivity during the calendar
GSK loses patent on Tykerb in India
This year has already seen IP setbacks in India for Novartis' leukaemia drug Glivec (imatinib), Merck &Co's Januvia (sitagliptin) diabetes franchise and Singulair (montelukast), Roche's Pegasys (peginterferon alfa-2a),
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- 10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm
- Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia
- EC approves Menarini Group’s Orserdu for advanced or metastatic breast cancer
- Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits
- Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma
- MIT study reveals why certain immunotherapies do not always work
No results were found
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
